- Home
- ZIP vs ABVX Comparison
ZIP vs ABVX Comparison
Compare ZIP & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- ABVX
- Stock Information
- Founded
- ZIP 2010
- ABVX 2013
- Country
- ZIP United States
- ABVX France
- Employees
- ZIP N/A
- ABVX N/A
- Industry
- ZIP Diversified Commercial Services
- ABVX
- Sector
- ZIP Consumer Discretionary
- ABVX
- Exchange
- ZIP Nasdaq
- ABVX Nasdaq
- Market Cap
- ZIP 784.5M
- ABVX 722.3M
- IPO Year
- ZIP 2021
- ABVX N/A
- Fundamental
- Price
- ZIP $6.96
- ABVX $8.08
- Analyst Decision
- ZIP Hold
- ABVX Strong Buy
- Analyst Count
- ZIP 6
- ABVX 7
- Target Price
- ZIP $9.80
- ABVX $37.86
- AVG Volume (30 Days)
- ZIP 464.2K
- ABVX 162.8K
- Earning Date
- ZIP 02-25-2025
- ABVX 03-24-2025
- Dividend Yield
- ZIP N/A
- ABVX N/A
- EPS Growth
- ZIP N/A
- ABVX N/A
- EPS
- ZIP 0.03
- ABVX N/A
- Revenue
- ZIP $498,903,000.00
- ABVX $9,676,417.00
- Revenue This Year
- ZIP N/A
- ABVX $31.67
- Revenue Next Year
- ZIP N/A
- ABVX $759.77
- P/E Ratio
- ZIP $236.57
- ABVX N/A
- Revenue Growth
- ZIP N/A
- ABVX 100.87
- 52 Week Low
- ZIP $6.51
- ABVX $5.50
- 52 Week High
- ZIP $13.03
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- ZIP 38.68
- ABVX 75.42
- Support Level
- ZIP $7.15
- ABVX $5.88
- Resistance Level
- ZIP $8.00
- ABVX $7.57
- Average True Range (ATR)
- ZIP 0.34
- ABVX 0.46
- MACD
- ZIP -0.05
- ABVX 0.24
- Stochastic Oscillator
- ZIP 19.56
- ABVX 97.68
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It was founded to make meaningful connections between job seekers and employers. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.